Gene therapy drug development in 2026 confronts a period of measured progress rather than breakthrough momentum. The first quarter of this year brought only two new regulatory approvals globally across gene, cell, and RNA therapies, signaling a slower approval cadence even as the development pipeline continues to expand. With 46 FDA-approved advanced therapies now available and 264 agents under investigation in the U.S. alone, the field faces a critical gap between developmental activity and regulatory conversion: approximately 10 agents approach FDA decisions annually, yet actual approvals settle at 5-7 per year on average.
This …









